Citius Pharmaceuticals Dirección
Dirección controles de criterios 2/4
Citius Pharmaceuticals' El consejero delegado es Leonard Mazur , nombrado en Mar 2016, tiene un mandato de 7.75 años. la remuneración anual total es $1.19M , compuesta por 33.6% salario y 66.4% primas, incluidas acciones y opciones de la empresa. posee directamente 6.46% de las acciones de la empresa, por valor de $8.36M . La antigüedad media del equipo directivo y del consejo de administración es de 2.9 años y 7.8 años respectivamente.
Información clave
Leonard Mazur
Chief Executive Officer (CEO)
US$2.0m
Compensación total
Porcentaje del salario del CEO | 24.0% |
Permanencia del CEO | 8.1yrs |
Participación del CEO | 6.4% |
Permanencia media de la dirección | 3.3yrs |
Promedio de permanencia en la Junta Directiva | 8yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
Apr 06We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate
Dec 08Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?
Aug 01We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Apr 12Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation
Dec 25Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK
Sep 28Citius Pharmaceuticals GAAP EPS of -$0.06
Aug 11Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely
Aug 05Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK
Jul 12Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Jul 05Critical Care Biopharma - Citius Pharmaceuticals
Apr 13Citius: 2022 Is A Year Of Catalysts
Mar 28We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Dec 04Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization
Sep 26Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth
Aug 28Citius: Halt For Superiority On The Horizon
Jun 15We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
May 15Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results
Apr 26Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?
Dec 18Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$39m |
Sep 30 2023 | US$2m | US$475k | -US$34m |
Jun 30 2023 | n/a | n/a | -US$31m |
Mar 31 2023 | n/a | n/a | -US$31m |
Dec 31 2022 | n/a | n/a | -US$28m |
Sep 30 2022 | US$1m | US$400k | -US$34m |
Jun 30 2022 | n/a | n/a | -US$31m |
Mar 31 2022 | n/a | n/a | -US$29m |
Dec 31 2021 | n/a | n/a | -US$26m |
Sep 30 2021 | US$788k | US$348k | -US$25m |
Jun 30 2021 | n/a | n/a | -US$24m |
Mar 31 2021 | n/a | n/a | -US$21m |
Dec 31 2020 | n/a | n/a | -US$21m |
Sep 30 2020 | US$550k | US$250k | -US$18m |
Jun 30 2020 | n/a | n/a | -US$17m |
Mar 31 2020 | n/a | n/a | -US$17m |
Dec 31 2019 | n/a | n/a | -US$16m |
Sep 30 2019 | US$473k | US$250k | -US$16m |
Jun 30 2019 | n/a | n/a | -US$15m |
Mar 31 2019 | n/a | n/a | -US$12m |
Dec 31 2018 | n/a | n/a | -US$13m |
Sep 30 2018 | US$398k | US$250k | -US$13m |
Jun 30 2018 | n/a | n/a | -US$13m |
Mar 31 2018 | n/a | n/a | -US$13m |
Dec 31 2017 | n/a | n/a | -US$11m |
Sep 30 2017 | US$307k | US$250k | -US$10m |
Compensación vs. Mercado: Leonard($USD1.98M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD662.75K).
Compensación vs. Ingresos: Leonardha aumentado mientras la empresa no es rentable.
CEO
Leonard Mazur (78 yo)
8.1yrs
Permanencia
US$1,981,113
Compensación
Mr. Leonard L. Mazur has been Chief Executive Officer of Citius Pharmaceuticals, Inc. since May 01, 2022. He serves as an Independent Director of Tharimmune, Inc. (formerly known as Hillstream BioPharma, I...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Co-Founder | 8.1yrs | US$1.98m | 6.45% $ 7.7m | |
Co-Founder & Executive Vice Chairman | 8.5yrs | US$1.59m | 1.25% $ 1.5m | |
Executive VP & Chief Medical Officer | 3.8yrs | US$1.17m | 0% $ 0 | |
Chief Business Officer | 6.4yrs | US$809.00k | 0.038% $ 45.5k | |
Executive Vice President of Operations | 8.1yrs | sin datos | sin datos | |
Vice President of Investor Relations & Corporate Communications | no data | sin datos | sin datos | |
Senior VP and Head of Clinical Operations & Quality Assurance | 2.2yrs | sin datos | sin datos | |
Senior Vice President of Business Strategy | 3.3yrs | sin datos | sin datos | |
Executive Vice President of Chemistry | 2.4yrs | sin datos | sin datos | |
Executive Vice President of Quality Assurance | 1.3yrs | sin datos | sin datos | |
Executive Vice President of Regulatory Affairs | less than a year | sin datos | sin datos |
3.3yrs
Permanencia media
68.5yo
Promedio de edad
Equipo directivo experimentado: CTXREl equipo directivo de la empresa se considera experimentado (2.9 años de antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Co-Founder | 9.6yrs | US$1.98m | 6.45% $ 7.7m | |
Co-Founder & Executive Vice Chairman | 8.5yrs | US$1.59m | 1.25% $ 1.5m | |
Independent Director | 1.2yrs | US$150.13k | 0% $ 0 | |
ARDS Scientific Advisory Board Member | no data | sin datos | sin datos | |
Independent Director | 8.5yrs | US$196.97k | 0% $ 0 | |
Independent Director | 8.1yrs | US$190.97k | 0% $ 0 | |
Independent Director | 7.8yrs | US$190.97k | 0% $ 0 | |
Chairman of Scientific Advisory Board | no data | sin datos | sin datos | |
Member of Scientific Advisory Board | no data | sin datos | sin datos | |
Member of Scientific Advisory Board | 5.8yrs | sin datos | sin datos | |
ARDS Scientific Advisory Board Member | 2.8yrs | sin datos | sin datos | |
ARDS Scientific Advisory Board Member | no data | sin datos | sin datos |
8.0yrs
Permanencia media
76yo
Promedio de edad
Junta con experiencia: La junta directiva de CTXR se considera experimentada (7.8 años de antigüedad promedio).